NCT05961098View on ClinicalTrials.gov

A Study of RBD1016 in CHB Participants

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

April 21, 2025

Study Completion Date

December 15, 2025

Conditions
Chronic Hepatitis B
Interventions
DRUG

RBD1016

RBD1016 with NAs background treatment will be explored.

Trial Locations (4)

Unknown

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

141 86

Karolinska University Hospital, Stockholm

752 37

Clinical Trial Consultants AB, Uppsala

All Listed Sponsors
lead

Suzhou Ribo Life Science Co. Ltd.

INDUSTRY

NCT05961098 - A Study of RBD1016 in CHB Participants | Biotech Hunter | Biotech Hunter